Device Trial Radar · NCT03200106
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
Last checked: Nov 19, 2026Latest source record: Apr 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Aug 1, 2017
Primary completion
Feb 28, 2018
Study completion Mar 31, 2018
Sponsor
- Lead sponsor
- Sequana Medical N.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 27, 2017
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatment of malignant ascites with the alfapump offers a new treatment option for this patient group. So far, there is no systematic analysis of patients with this indication available in the literature. This retrospective analysis offers the possibility to assemble already existing data within a reasonably short time frame. Based on this analysis, a prospective analysis can be designed.
Conditions
- Malignant Ascites
Interventions
AlfapumpDevice
Alfapump implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in frequency of LVP after implantation of the alfapumpTime frame: 3-6 months post implant
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Universitätsklinikum Leipzig
Leipzig, Germany
Inselspital
Bern, Switzerland
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.